Camrelizumab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	82	43	33	276	—	—	Apr 6, 2016
Malignant Liver Neoplasm	Phase3	Phase 3	12	7	6	29	—	—	2016-10
Malignant Breast Neoplasm	Phase3	Phase 3	10	6	2	20	—	—	Apr 27, 2016
Malignant Esophageal Neoplasm	Phase3	Phase 3	6	2	5	27	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Low on-treatment bTMB1
Camrelizumab +

Clinical trials

Trials with this intervention (288)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 288 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05043688	Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.	active not recruiting	Phase 3	426	Zhigang LiOTHER	1	Sep 17, 2026	clinicaltrials
NCT05772273	PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT	recruiting	N/A	43